查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1471954

肺给药系统市场规模和预测、全球和区域份额、趋势和成长机会分析报告范围：按产品、适应症、配销通路、最终用户和地理位置

Pulmonary Drug Delivery Systems Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product, Indication, Distribution Channel, End User, and Geography
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

肺部给药系统市场规模预计将从2023年的497.1亿美元成长到2031年的731.4亿美元；预计 2023 年至 2031 年市场复合年增长率为 4.9%。

肺部给药是指将药物直接输送到肺部的技术和方法。这些系统旨在透过吸入将气溶胶直接输送至上皮细胞和呼吸道上皮。这些系统利用肺部的大表面积、薄上皮层和丰富的血液供应来促进药物的快速有效吸收。肺部给药系统市场的成长归因于呼吸系统疾病负担的增加和公司不断增加的策略性倡议。然而，与肺部药物输送系统的批准相关的监管问题阻碍了肺部药物输送系统市场的成长。

最近，已采取各种措施和措施来提高人们对呼吸系统疾病的认识并进行教育，促使患者获得适合此类疾病的药物和治疗。 Cipla 为慢性气道疾病患者开展了一项名为「Breathefree」的公共服务计划。 Berok Zindagi 的计画旨在让气喘患者发挥真正的潜力，并透过使用吸入器过着不可阻挡的生活。 Berok Zindagi 被精心设计为一种工具，为消费者提供他们所需的所有信息，让他们毫不犹豫地使用吸入器，并直面与吸入疗法相关的耻辱。透过使用多语言和多媒体教育资源来提高对疾病和吸入器的认识，教育工作者确保为患者提供咨询。透过 600 多名 Breathefree 教育工作者和 5,600 多名医生的努力，Breathefree Clinic 服务为印度各地超过 1,25,000 多名呼吸系统患者提供服务。

疾病预防控制中心的国家气喘控制计划也提供资金，用于教育气喘患者接受有关其病情的教育。因此，此类措施可能会提高人们对呼吸系统疾病的认识，为肺部给药系统市场的成长提供新的机会。

基于配销通路的见解

根据配销通路，肺部给药系统市场分为医院药房、零售药房和电子商务。到 2023 年，医院药局细分市场将占据重要的肺部给药系统市场。医院药局是整合到医院、诊所、毒物控制中心、住宿护理机构的药物资讯中心和药物依赖设施中心等医疗保健中心的专业药局。这些药房提供的主要好处是支援大量库存的储存、现场提供各种药品以及对医疗保健计划下购买的药品进行报销。医院药局不是零售场所；他们通常为住院患者提供药物。因此，他们不向公众提供处方服务。因此，专业治疗药物的容易取得有助于患者倾向于医院药房，这对肺部药物输送系统市场的成长有正面影响。

基于最终用户的见解

根据最终用户，肺部给药系统市场分为医院和诊所以及家庭护理。 2023 年，医院和诊所部门在肺部给药系统市场中占有重要份额。

美国食品药物管理局、世界卫生组织和疾病管制与预防中心是在准备肺部药物输送系统市场报告时提到的主要和次要来源之一。

目录

第 1 章：简介

第 2 章：执行摘要

  • 重要见解
  • 市场吸引力分析

第 3 章：研究方法

第 4 章：肺部给药系统市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链供应商名单

第 5 章：肺部给药系统市场 - 主要市场动态

  • 主要市场驱动因素
  • 主要市场限制
  • 主要市场机会
  • 未来的趋势
  • 驱动因素和限制因素的影响分析

第 6 章：肺部给药系统市场 - 全球市场分析

  • 肺部给药系统 - 全球市场概览
  • 肺部给药系统 - 全球市场与 2031 年预测

第 7 章：肺部给药系统市场 - 收入分析 - 按产品，2021-2031 年

  • 概述
  • 干粉吸入器
  • 定量吸入器
  • 雾化器

第 8 章：肺部给药系统市场 - 收入分析 - 按适应症分类，2021-2031 年

  • 概述
  • 慢性阻塞性肺臟疾病
  • 气喘
  • 囊肿纤维化
  • 其他的

第 9 章：肺部给药系统市场 - 收入分析 - 按配销通路，2021-2031 年

  • 概述
  • 医院药房
  • 零售药局
  • 电子商务

第 10 章：肺部给药系统市场 - 收入分析 - 按最终用户，2021-2031 年

  • 概述
  • 医院和诊所
  • 居家护理

第 11 章：肺部给药系统市场 - 收入分析，2021-2031 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥

註 - 将为以下提到的地区/国家提供类似的分析

  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 12 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第13章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与专注

第 14 章：肺部给药系统市场 - 主要公司概况

  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc
  • Novartis AG
  • Koninklijke Philips NV
  • Cipla Inc.
  • OMRON Corp.
  • PARI GmbH
  • Glenmark Pharmaceuticals
  • Gilbert Technologies

第 15 章：附录

简介目录
Product Code: TIPHE100001256

The pulmonary drug delivery systems market size is expected to grow from US$ 49.71 billion in 2023 to US$ 73.14 billion by 2031; the market is projected to register a CAGR of 4.9% during 2023-2031.

Pulmonary drug delivery refers to the technologies and methods used to deliver medications directly into the lungs. These systems are aimed at targeting the delivery of aerosols directly to epithelial cells and respiratory epithelium by means of inhalation. These systems take advantage of the lung's large surface area, thin epithelial layer, and rich blood supply to facilitate rapid and efficient absorption of medications. The pulmonary drug delivery systems market growth is attributed to the increasing burden of respiratory diseases and growing strategic initiatives by companies. However, regulatory issues associated with the approval of pulmonary drug delivery systems hinder the growth of the pulmonary drug delivery systems market.

Recently, various initiatives and measures have been taken to create awareness and educate people regarding respiratory diseases, prompting patients to access suitable medications and treatments for such conditions. Cipla has a public service initiative called Breathefree for people with chronic airway diseases. Berok Zindagi's program seeks to enable asthmatics to reach their true potential and lead lives that are unstoppable with the use of an inhaler. Berok Zindagi has been crafted as a tool to arm consumers with all the information they require to embrace inhalers without reluctance and confront the stigma associated with inhalation therapy. By using multilingual and multimedia educational resources to raise awareness about illnesses and inhalers, educators ensure patient counseling. Through the efforts of 600+ Breathefree Educators and 5600+ doctors, the Breathefree Clinic service serves over 1,25,000+ respiratory patients throughout India.

CDC's National Asthma Control Program also provides funds for educating patients with asthma to receive education regarding their condition. Thus, such initiatives are likely to increase awareness about respiratory diseases, offering new opportunities for the growth of the pulmonary drug delivery systems market.

Distribution Channel-Based Insights

Based on distribution channel, the pulmonary drug delivery systems market is categorized into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment held a significant pulmonary drug delivery systems market share in 2023. In addition, the e-commerce segment is expected to register the highest CAGR during the forecast period. Hospital pharmacies are specialized pharmacies integrated into healthcare centers such as hospitals, clinics, poison control centers, residential care facilities' drug information centers, and drug dependency facility centers. Capacities to support the storage of extensive stocks, availability of various medicines on the spot, and reimbursement on the drugs purchased under healthcare plans are the primary benefits conferred by these pharmacies. Hospital pharmacies are not retail establishments; they typically provide medications for hospitalized patients. Therefore, they don't provide prescription services to the public. Hence, the ease of availability of specialized therapeutics contributes to the inclination of patients toward hospital pharmacies, which is positively influencing the pulmonary drug delivery systems market growth.

End User-Based Insights

Based on end user, the pulmonary drug delivery systems market is categorized into hospitals & clinics and homecare. The hospitals & clinics segment held a significant pulmonary drug delivery systems market share in 2023. The homecare segment is estimated to register a higher CAGR during 2023-2031.

The US Food and Drug Administration, the World Health Organization, and the Centers for Disease Control and Prevention are among the primary and secondary sources referred to while preparing the pulmonary drug delivery systems market report.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Pulmonary Drug Delivery Systems Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Pulmonary Drug Delivery Systems Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Pulmonary Drug Delivery Systems Market - Global Market Analysis

  • 6.1 Pulmonary Drug Delivery Systems - Global Market Overview
  • 6.2 Pulmonary Drug Delivery Systems - Global Market and Forecast to 2031

7. Pulmonary Drug Delivery Systems Market - Revenue Analysis (USD Million) - By Product, 2021-2031

  • 7.1 Overview
  • 7.2 Dry Powder Inhalers
  • 7.3 Metered Dose Inhalers
  • 7.4 Nebulizers

8. Pulmonary Drug Delivery Systems Market - Revenue Analysis (USD Million) - By Indication, 2021-2031

  • 8.1 Overview
  • 8.2 Chronic Obstructive Pulmonary Disease
  • 8.3 Asthma
  • 8.4 Cystic Fibrosis
  • 8.5 Others

9. Pulmonary Drug Delivery Systems Market - Revenue Analysis (USD Million) - By Distribution Channel, 2021-2031

  • 9.1 Overview
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 E-commerce

10. Pulmonary Drug Delivery Systems Market - Revenue Analysis (USD Million) - By End User, 2021-2031

  • 10.1 Overview
  • 10.2 Hospitals and Clinics
  • 10.3 Homecare

11. Pulmonary Drug Delivery Systems Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 11.1 North America
    • 11.1.1 North America Pulmonary Drug Delivery Systems Market Overview
    • 11.1.2 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts to 2031
    • 11.1.3 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts and Analysis - By Product
    • 11.1.4 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts and Analysis - By Indication
    • 11.1.5 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 11.1.6 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts and Analysis - By End User
    • 11.1.7 North America Pulmonary Drug Delivery Systems Market Revenue and Forecasts and Analysis - By Countries
      • 11.1.7.1 United States Pulmonary Drug Delivery Systems Market
        • 11.1.7.1.1 United States Pulmonary Drug Delivery Systems Market, by Product
        • 11.1.7.1.2 United States Pulmonary Drug Delivery Systems Market, by Indication
        • 11.1.7.1.3 United States Pulmonary Drug Delivery Systems Market, by Distribution Channel
        • 11.1.7.1.4 United States Pulmonary Drug Delivery Systems Market, by End User
      • 11.1.7.2 Canada Pulmonary Drug Delivery Systems Market
        • 11.1.7.2.1 Canada Pulmonary Drug Delivery Systems Market, by Product
        • 11.1.7.2.2 Canada Pulmonary Drug Delivery Systems Market, by Indication
        • 11.1.7.2.3 Canada Pulmonary Drug Delivery Systems Market, by Distribution Channel
        • 11.1.7.2.4 Canada Pulmonary Drug Delivery Systems Market, by End User
      • 11.1.7.3 Mexico Pulmonary Drug Delivery Systems Market
        • 11.1.7.3.1 Mexico Pulmonary Drug Delivery Systems Market, by Product
        • 11.1.7.3.2 Mexico Pulmonary Drug Delivery Systems Market, by Indication
        • 11.1.7.3.3 Mexico Pulmonary Drug Delivery Systems Market, by Distribution Channel
        • 11.1.7.3.4 Mexico Pulmonary Drug Delivery Systems Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

  • 11.2 Europe
    • 11.2.1 Germany
    • 11.2.2 France
    • 11.2.3 Italy
    • 11.2.4 Spain
    • 11.2.5 United Kingdom
    • 11.2.6 Rest of Europe
  • 11.3 Asia-Pacific
    • 11.3.1 Australia
    • 11.3.2 China
    • 11.3.3 India
    • 11.3.4 Japan
    • 11.3.5 South Korea
    • 11.3.6 Rest of Asia-Pacific
  • 11.4 Middle East and Africa
    • 11.4.1 South Africa
    • 11.4.2 Saudi Arabia
    • 11.4.3 U.A.E
    • 11.4.4 Rest of Middle East and Africa
  • 11.5 South and Central America
    • 11.5.1 Brazil
    • 11.5.2 Argentina
    • 11.5.3 Rest of South and Central America

12. Industry Landscape

  • 12.1 Mergers and Acquisitions
  • 12.2 Agreements, Collaborations, Joint Ventures
  • 12.3 New Product Launches
  • 12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

  • 13.1 Heat Map Analysis by Key Players
  • 13.2 Company Positioning and Concentration

14. Pulmonary Drug Delivery Systems Market - Key Company Profiles

  • 14.1 AstraZeneca plc
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments

Note - Similar information would be provided for below list of companies

  • 14.2 Boehringer Ingelheim International GmbH
  • 14.3 GlaxoSmithKline plc
  • 14.4 Novartis AG
  • 14.5 Koninklijke Philips NV
  • 14.6 Cipla Inc.
  • 14.7 OMRON Corp.
  • 14.8 PARI GmbH
  • 14.9 Glenmark Pharmaceuticals
  • 14.10 Gilbert Technologies

15. Appendix

  • 15.1 Glossary
  • 15.2 About The Insight Partners
  • 15.3 Market Intelligence Cloud